The Defense Advanced Research Projects Agency announced a five-year, $24.6 million grant to Moderna Therapeutics to advance the three-year-old biotech company's messenger RNA technology. "By making this grant, the agency is betting on what could become a superfast, cheap, and unusually adaptable method for fighting today’s known pandemic threats, and the unknown threats of the future," Luke Timmerman writes.

Full Story:

Related Summaries